SCHEDULE: RA Capital Management Amends Climb Bio Stake

RA Capital Management, L.P. and its affiliates have updated their Schedule 13D filing, reporting a beneficial ownership of 33.0% in Climb Bio, Inc. following a board appointment and stock distribution.

Summary

• RA Capital Management, L.P. and its affiliated entities (collectively, the "Reporting Persons") have filed an amendment to their Schedule 13D, reporting their beneficial ownership of Climb Bio, Inc. common stock.
• The Reporting Persons collectively beneficially own 23,249,186 shares of common stock, representing 33.0% of the outstanding shares.
• This ownership includes shares held directly by RA Capital Healthcare Fund, L.P. (16,934,205 shares, 24.1%) and RA Capital Nexus Fund III, L.P. (3,671,766 shares, 6.4%), among other holdings.
• A "Beneficial Ownership Blocker" provision in pre-funded warrants held by the Fund restricts exercise if it would cause beneficial ownership to exceed 33.0%.
• Dr. Breanna Celebi (O'Reilly), an Analyst at RA Capital, was appointed to Climb Bio's Board of Directors on June 29, 2026, replacing Dr. Andrew Levin.
• On July 2, 2026, Sera made an in-kind distribution of 2,479,872 shares of common stock to its members, with the Fund and Nexus Fund III receiving 433,672 and 805,391 shares, respectively.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive. While it confirms a significant stake and board representation, the "Beneficial Ownership Blocker" limits immediate upside from warrant exercise, and the filing is primarily an update on ownership rather than new strategic initiatives.

Positives

• RA Capital Management maintains a significant stake (33.0%) in Climb Bio, Inc., indicating continued strategic interest.
• The appointment of Dr. Breanna Celebi to the Board of Directors provides direct representation for RA Capital's interests.
• The in-kind distribution of shares to RA Capital funds increases their direct holdings.

Negatives

• The "Beneficial Ownership Blocker" limits the Fund's ability to exercise pre-funded warrants, capping its ownership at 33.0%.

Risks

• The "Beneficial Ownership Blocker" may prevent the Fund from increasing its stake beyond 33.0% through warrant exercise, potentially limiting future upside or strategic flexibility.
• Changes in board representation could signal shifts in strategic direction or governance, the long-term impact of which is yet to be determined.

Future Outlook

The filing does not contain specific forward-looking statements or guidance from Climb Bio, Inc. It primarily details the current beneficial ownership and recent corporate actions by RA Capital Management.

Management Comments

• "The Fund is currently prohibited from exercising the Pre-Funded Warrants to the extent that such exercise would result in the Reporting Persons' beneficial ownership of more than 23,249,186 shares of common stock."
• "RA Capital serves as investment adviser for the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III and the Account and may be deemed a beneficial owner, for purposes of Section 13(d) of the Act of any securities of the Issuer held by the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III or the Account."
• "The Fund, the Nexus Fund, the Nexus Fund II and the Nexus Fund III have delegated to RA Capital the sole power to vote and the sole power to dispose of all securities held in the Fund, the Nexus Fund, the Nexus Fund II and the Nexus Fund III, and each of these funds has divested themselves of voting and investment power over the reported securities they hold and may not revoke that delegation on less than 61 days' notice."

Industry Context

StockSavvy.ai notes that this Schedule 13D amendment reflects active portfolio management by a significant institutional investor in the biotechnology sector. The increase in direct shareholdings and board representation by RA Capital suggests a continued strategic focus on Climb Bio, Inc., a common practice for specialized healthcare investment firms seeking to influence or monitor portfolio company development.

Comparison to Industry Standards

• RA Capital Management's 33.0% stake in Climb Bio, Inc. is substantial for a biotechnology company, often indicating a significant influence or activist position, which is common for specialized healthcare funds like RA Capital.
• The "Beneficial Ownership Blocker" is a standard anti-takeover or ownership limitation provision found in some warrant agreements, designed to prevent a single entity from exceeding a certain ownership threshold without prior consent or triggering specific events.
• The appointment of an investor representative to the board is a typical governance mechanism in venture capital and private equity, ensuring alignment between the investor and the company's strategic direction.

Management Changes

Stakeholder Impact

• Shareholders: The continued significant ownership by RA Capital Management may influence corporate strategy and governance, potentially impacting long-term shareholder value. The "Beneficial Ownership Blocker" may affect the dilutive impact of warrant exercises.
• Employees: The board appointment of an investor representative could lead to shifts in strategic priorities or operational focus.
• Creditors: No direct impact mentioned, but significant changes in company strategy influenced by major shareholders could indirectly affect financial stability.

Next Steps

• Monitor Climb Bio, Inc.'s strategic developments and financial performance under the continued influence of RA Capital Management.
• Observe any future actions by RA Capital Management regarding their stake, particularly concerning the limitations imposed by the "Beneficial Ownership Blocker".

Key Dates

Recommendation

The filing indicates a stable, significant ownership position by a key investor and a board seat, suggesting continued strategic involvement. However, the "Beneficial Ownership Blocker" limits immediate upside from warrant exercise, and the filing itself is an update rather than a catalyst for significant price movement. Therefore, a 'hold' recommendation is appropriate pending further developments or company performance updates.

Keywords

Climb Bio, RA Capital Management, Schedule 13D, Beneficial Ownership, Common Stock, Board of Directors, Warrants, SEC Filing, Amendment